{"entity":{"id":"nct07541001","kind":"trial","name":"PRL3-Zumab in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.","summary":"PRL3-Zumab in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07541001 by Intra-IMMUSG Pte Ltd, with 60 participants enrolled, started 2021-08-30 and due to reach its primary completion in 2026-06-01. Interventions recorded: PRL3-ZUMAB.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07541001","url":"https://clinicaltrials.gov/study/NCT07541001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["intra-immusg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07541001","phase":"2","setting":"An Open Label, Multicenter, Safety and Efficacy Phase II Study of PRL3-Zumab in Solid Tumors","sponsor":"Intra-IMMUSG Pte Ltd","enrolled":60,"outcomes":[]},"route":"/trials/nct07541001/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/"}]}}